Advertisement
ACB vs EVO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a StrongBuy and EVO is a Hold.
ACB's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ACB turned positive on November 03, 2026. Looking at past instances where ACB's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on ACB as a result. In 69 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
ACB moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ACB crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +24.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACB advanced for three days, in 180 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 79 of 116 cases where ACB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
ACB broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.629) is normal, around the industry mean (6.379). P/E Ratio (-2.701) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.984) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
EVO in upward trend: 10-day moving average broke above 50-day moving average on November 10, 2026
The 10-day moving average for EVO crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on EVO as a result. In 67 of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for EVO just turned positive on October 20, 2026. Looking at past instances where EVO's MACD turned positive, the stock continued to rise in 29 of 41 cases over the following month. The odds of a continued upward trend are 71%.
EVO moved above its 50-day moving average on November 05, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +14.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVO advanced for three days, in 187 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 85 of 140 cases where EVO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The 10-day RSI Indicator for EVO moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In 15 of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 58 cases where EVO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
EVO broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. EVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.746) is normal, around the industry mean (6.379). EVO's P/E Ratio (476.190) is considerably higher than the industry average of (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.695) is also within normal values, averaging (183.387).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
ACB | EVO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 30 | 23 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 91 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 96 | |
PRICE GROWTH RATING 1..100 | 36 | 62 | |
P/E GROWTH RATING 1..100 | 98 | 2 | |
SEASONALITY SCORE 1..100 | 32 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ACB's Valuation (24) in the Pharmaceuticals Other industry is significantly better than the same rating for EVO (91) in the null industry. This means that ACB’s stock grew significantly faster than EVO’s over the last 12 months.
ACB's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as EVO (100) in the null industry. This means that ACB’s stock grew similarly to EVO’s over the last 12 months.
ACB's SMR Rating (96) in the Pharmaceuticals Other industry is in the same range as EVO (96) in the null industry. This means that ACB’s stock grew similarly to EVO’s over the last 12 months.
ACB's Price Growth Rating (36) in the Pharmaceuticals Other industry is in the same range as EVO (62) in the null industry. This means that ACB’s stock grew similarly to EVO’s over the last 12 months.
EVO's P/E Growth Rating (2) in the null industry is significantly better than the same rating for ACB (98) in the Pharmaceuticals Other industry. This means that EVO’s stock grew significantly faster than ACB’s over the last 12 months.
| ACB | EVO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 83% | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 89% | 2 days ago 78% |
| Momentum ODDS (%) | 2 days ago 77% | 2 days ago 67% |
| MACD ODDS (%) | 2 days ago 84% | 2 days ago 71% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 67% |
| TrendMonth ODDS (%) | 2 days ago 79% | 2 days ago 62% |
| Advances ODDS (%) | 8 days ago 77% | 7 days ago 68% |
| Declines ODDS (%) | 2 days ago 84% | 10 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 68% | 2 days ago 61% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACB’s FA Score shows that 1 FA rating(s) are green while EVO’s FA Score has 1 green FA rating(s).
- ACB’s FA Score: 1 green, 4 red.
- EVO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACB’s TA Score shows that 6 TA indicator(s) are bullish while EVO’s TA Score has 6 bullish TA indicator(s).
- ACB’s TA Score: 6 bullish, 4 bearish.
- EVO’s TA Score: 6 bullish, 4 bearish.
Price Growth
ACB (@Pharmaceuticals: Generic) experienced а -0.97% price change this week, while EVO (@Pharmaceuticals: Generic) price change was +9.03% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.20%. For the same industry, the average monthly price growth was -6.54%, and the average quarterly price growth was +10.31%.
Reported Earning Dates
ACB is expected to report earnings on Feb 10, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.20% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
EVO and
Correlation & Price change
A.I.dvisor indicates that over the last year, EVO has been loosely correlated with SNDL. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if EVO jumps, then SNDL could also see price increases.
| Ticker / NAME | Correlation To EVO | 1D Price Change % | ||
|---|---|---|---|---|
| EVO | 100% | -2.87% | ||
| SNDL - EVO | 42% Loosely correlated | -0.71% | ||
| PRGO - EVO | 31% Poorly correlated | -0.71% | ||
| SUPN - EVO | 28% Poorly correlated | +4.09% | ||
| ACET - EVO | 26% Poorly correlated | +0.33% | ||
| ACB - EVO | 26% Poorly correlated | -0.97% | ||
More | ||||